Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02627716
Other study ID # 2014_04
Secondary ID 2014-A00911-46
Status Recruiting
Phase N/A
First received
Last updated
Start date December 2014
Est. completion date July 2022

Study information

Verified date September 2020
Source University Hospital, Lille
Contact Elsa MAITRE
Phone 1.45.65.61.21
Email e.maitre@ch-sainte-anne.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Joint Crisis Plan = SOS Plan is a reference to a particular form of psychiatric advance directive which involves the patient, the healthcare team, their relatives and a third party caregiver as intermediary for the project.

The main objective is to evaluate the effectiveness of the SOS Plan (JCP) in terms of the reduction in hospitalisations within 18 months of its development by comparison to the standard psychiatric care.

Thus, the investigators' proposal is that SOS Plan's are regularly reassessed every 6 months and again where there is an unplanned psychiatric readmission that lasts beyond two weeks.

Single blind multicentre randomised trial with parallel control groups.

Effectiveness study of a psychiatric care strategy.


Description:

Single blind multicentre randomised trial with parallel control groups.

2 groups:

- SOS Intervention Group: benefits from the SOS Plan in addition to the usual follow-ups

- "Control" Group: receive no additional intervention (only receive the routine follow-ups)

OBJECTIVES :

- To evaluate the effectiveness of the SOS Plan (JCP) in terms of the reduction in hospitalisations within 18 months of its development by comparison to the standard psychiatric care

- To evaluate :

1. the cumulative length of hospitalisations (in days) in the two years following the development of the SOS plan

2. the type of hospitalisation (voluntary or compulsory)

3. the number of hospitalisations for a given subject

4. the number of crisis situations that may require the use of the SOS Plan

5. the clinical condition of the patient

6. the patient with the most responses to the SOS Plan in socio-demographic terms

7. the patient satisfaction in using the SOS Plan

8. the decisional autonomy during treatment

9. the quality of the therapeutic alliance

10. the length of the meeting to develop the SOS Plan

11. the quality of life

12. the medico-economic impact

EXECUTION OF PRACTICAL RESEARCH :

1. The inclusion visit will be completed apart from a period of acute psychiatric decompensation, while the patient is capable of consenting to treatment. The inclusion visit will be completed within a hospital department before the patient is finally released from hospitalisation or during an outpatient follow-up.

This involves placing the patient on the Positive And Negative Syndrome Scale (PANSS) to ensure that the patient's clinical condition allows him to consent to treatment. A score above 95 excludes the patient.

The investigator also outlines the study and schedules visits. The patient then signs both the information letter and informed consent.

A urine pregnancy test will be carried out on women of childbearing age.

2. Randomisation will be performed by a member of the SOS regional-referral team.

For patients in the SOS Intervention group:

- Preparatory interview with an SOS regional referrer

- SOS Plan development meeting in the presence of the patient, the treating psychiatrist, one or more relatives, and an SOS regional referrer

For patients in the control group: tracking the continuation of psychiatric care according to the standard care terms

3 ) Follow-up visits: for the two groups: 4 visits M6, M12, M18, M24 At each visit: meeting with an independent regional SOS assessor blind to allocation.

For both of the groups:

- Assessment of the clinical condition: placement on the PANSS scale

- Number of psychiatric hospitalisations, types of hospitalisation, duration of hospitalisation since the last visit

- Satisfaction assessment (numeric scale), of the therapeutic alliance (WAI), of decision-making autonomy (API), of quality of life (SF-36)

For the SOS Intervention group:

- Updating the SOS Plan after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks.

- Updating the SOS Plan every 6 months in the absence of hospitalisation


Recruitment information / eligibility

Status Recruiting
Enrollment 210
Est. completion date July 2022
Est. primary completion date January 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Aged between 18 and 65 years

- Diagnosed with schizophrenia or schizoaffective disorder according to criteria specified in DSM

- Psychiatric inpatient or an outpatient with a specialised framework of psychiatric follow-ups

- Patient has been hospitalised at least once in a psychiatric department within the previous 2 years

- Adults under protective measures can be included (guardianship/supervision). Consent will also be sought from the guardian or trusted person.

- Registered for social security

Exclusion Criteria:

- Refusal to participate in the study

- Unable to give his or her written consent

- Patients detained

- Pregnant or lactating women

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
SOS Plan
It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite. The booklet outlines four avenues to consider: Contact details / contact person Treatment and current follow-ups Medical care in the event of a crisis Practical aid in the event of a crisis Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks.

Locations

Country Name City State
France University Hospital, Brest Brest
France University Hospital, Caen Caen
France University Hosiptal, Lille Lille
France Sainte-Anne Hospital, Paris Paris

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Lille Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary incidence of the first psychiatric hospitalisation the incidence of the first psychiatric hospitalisation within 18 months following inclusion 18 months
Secondary cumulative time in days of psychiatric hospitalisations the cumulative time, in days, of psychiatric hospitalisations in the two years following inclusion 2 years
Secondary types of psychiatric hospitalisations the types of psychiatric hospitalisation: voluntary (SL) or compulsory (SDT) 2 years
Secondary number of hospitalisations the number of hospitalisations for each subject 2 years
Secondary number of emergency psychiatric consultations the number of emergency psychiatric consultations 2 years
Secondary clinical assessment by the PANSS scale PANSS score (intensity and qualitative aspects of the clinical situation) every 6 months during 2 years
Secondary patient satisfaction score at a numeric scale of patient satisfaction every 6 months during 2 years
Secondary Autonomy Preference Index decision making-autonomy assessment every 6 months during 2 years
Secondary Working Alliance Inventory the working alliance assessment every 6 months during 2 years
Secondary length of the meeting to develop the SOS Plan the length of the meeting to develop the SOS Plan in minutes every 6 months during 2 years
Secondary SF-36 quality of life quality of life assessment by the SF-36 every 6 months during 2 years
Secondary medical cost numbers of hospitalisations, of consultations, drugs consummation every 6 months during 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A